Loading...

Intellectia LogoIntellectia
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. 09926
09926 logo

09926 Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • AI Stock Picker
  • Swing Trading
  • SwingMax Portfolio
  • QuantAI Alpha Pick
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • Financial AI Agent
  • AI Screener
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
107.800
Open
100.500
VWAP
105.57
Vol
5.66M
Mkt Cap
--
Low
99.600
Amount
597.02M
EV/EBITDA(TTM)
--
Total Shares
--
EV
11.65B
EV/OCF(TTM)
--
P/S(TTM)
32.62

Events Timeline

No data

No data

News

aastocks
4.5
02-06aastocks
HKD4.3 Billion Net Inflow from Southbound Trading into TENCENT
  • Southbound Trading Inflows: TENCENT (00700.HK) saw significant Southbound Trading net inflows totaling HKD4.3 billion, while other stocks like BABA-W (09988.HK) and POP MART (09992.HK) experienced notable short selling activity.

  • Market Activity Overview: TENCENT was the most active stock in both Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect, with substantial net inflows, while stocks like XIAOMI-W and AKESO faced the highest net outflows.

  • Short Selling Statistics: The short selling ratios for TENCENT, BABA-W, and POP MART were 15.248%, 19.556%, and 27.852% respectively, indicating a high level of market speculation.

  • Overall Market Sentiment: The total Southbound Trading net outflow was HKD0, accounting for 35.67% of the total transaction amount of HKD88.42 billion, reflecting fragile market sentiment according to JPM.

aastocks
4.5
01-19aastocks
CICC Identifies Possible 'Blue Chip' Stocks for HSI Semi-Annual Adjustment Predictions (Table)
  • CICC Report on HSI Adjustments: CICC predicts potential blue chip stocks for inclusion in the HSI based on semi-annual adjustments and quantitative criteria, highlighting companies like ZIJIN GOLD INTL and YUM CHINA.

  • Short Selling and Inflows: The report details short selling ratios and inflows for various stocks, indicating market activity and investor sentiment towards companies such as BEONE MEDICINES and XPENG-W.

  • Potential Replacements for HANG SENG BANK: Following the delisting of HANG SENG BANK, companies like STANCHART and SWIREPROPERTIES are identified as potential candidates to fill the vacancy.

  • Market Performance Overview: The report includes a snapshot of stock performance, with some companies experiencing gains while others face declines, reflecting the mixed market conditions.

aastocks
8.5
01-19aastocks
Duoning Biotech Seeks Hong Kong Listing; WUXI BIO is Its Largest Client
  • Company Listing: Shanghai Duoning Biotechnology has submitted a listing application to the Hong Kong Stock Exchange, with Morgan Stanley and Huatai International as joint sponsors.

  • Clientele and Services: The company provides bioprocess solutions and laboratory products to pharmaceutical companies, CROs, CDMOs, and research institutions, with major clients including top biopharmaceutical firms in China.

  • Key Clients: WuXi Biologics is highlighted as one of the largest clients and suppliers, along with other notable shareholders such as CSPC Pharma, Akeso, and Keymed Bio-B.

  • Market Activity: The article notes short selling activity and stock performance for several companies in the sector, indicating market dynamics and investor interest.

aastocks
6.5
01-13aastocks
KGI Projects HSI to Reach 30,000 by Year-End, Suggests 12 Stocks Including XPENG-W, UBTECH ROBOTICS, TENCENT, and BABA-W
  • China's GDP Growth Outlook: KGI estimates that external pressures will slow China's GDP growth to 4.6% this year, despite reduced risks from recent trade agreements.

  • HSI Forecast: KGI maintains a bullish outlook for the Hang Seng Index (HSI), predicting that Fed rate cuts will attract capital back into H- and A-shares, with a year-end target of 30,000, indicating a potential 14% increase.

  • Stock Recommendations: KGI has recommended 12 major stocks, including XPENG-W, UBTECH ROBOTICS, TENCENT, and BABA-W, highlighting their performance and short selling ratios.

  • Market Sentiment: The report reflects a positive sentiment towards the Chinese A-share market, driven by anticipated earnings growth, as noted by Jefferies.

aastocks
8.0
01-09aastocks
HKEX Introduces Six New Classes of Stock Options
  • New Stock Options Launch: HKEX is set to launch six new stock option classes on January 19, 2026, enhancing choices for investors in the single stock options market.

  • Included Stocks: The new options will include stocks such as ZIJIN GOLD INTL, WUXI APPTEC, BEONE MEDICINES, LAOPU GOLD, HORIZONROBOT-W, and AKESO, each with varying short selling data and ratios.

aastocks
4.0
01-05aastocks
Daiwa Selects INNOVENT BIO (01801.HK) and HENGRUI PHARMA (600276.SH) as Top Picks, Raises Target Price to HKD112
  • Market Overview: In 2025, the Chinese biopharmaceutical sector experienced significant growth, prompting Daiwa to suggest a selective investment strategy for 2026, focusing on quality stocks.

  • Top Stock Picks: Daiwa's recommended stocks include INNOVENT BIO, with a target price increase from HKD95 to HKD112, and HENGRUI PHARMA, maintaining a target price of RMB80.

  • Stock Downgrades: AKESO has been downgraded from Buy to Hold, despite an increase in its target price from HKD100 to HKD116, while CSPC PHARMA retains a Sell rating with a target price of HKD6.6.

  • Short Selling Data: The report includes short selling figures for the mentioned stocks, indicating varying levels of market activity and investor sentiment.

Wall Street analysts forecast 09926 stock price to rise
0 Analyst Rating
Wall Street analysts forecast 09926 stock price to rise
0 Buy
0 Hold
0 Sell
Current: 0.000
sliders
Low
Averages
High
Current: 0.000
sliders
Low
Averages
High
Daiwa
Daiwa
Buy
to
Hold
downgrade
$100 -> $116
AI Analysis
2026-01-05
Reason
Daiwa
Daiwa
Price Target
$100 -> $116
AI Analysis
2026-01-05
downgrade
Buy
to
Hold
Reason
Daiwa downgraded AKESO from Buy to Hold due to a lack of short-term catalysts. The firm noted that AKESO's only significant product, the PD-1/VEGF bispecific tumor immunotherapy drug Ivonescimab, is awaiting the release of important data (HARMONi-3 'progression-free survival' data) by the end of the year. Daiwa is taking a wait-and-see approach, looking for meaningful developments beyond Ivonescimab before making further investment decisions.
CICC
CICC
Outperform
to
NULL
downgrade
2025-10-22
Reason
CICC
CICC
Price Target
2025-10-22
downgrade
Outperform
to
NULL
Reason
The analyst rating for AKESO (09926.HK) is maintained as "Outperform" by CICC due to the impressive interim analysis data presented from the HARMONi-6 study and the revision of the HARMONi-3 trial protocol. CICC believes that the separate analysis of histological types will enable AKESO to obtain clinical data earlier and that increasing the enrolled population will enhance overall survival (OS) performance. However, the target price was cut by 18.2% to HKD184, reflecting a downward adjustment in the valuation center for innovative drugs in the Hong Kong stock market.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for 09926
Unlock Now

Valuation Metrics

The current forward P/E ratio for (09926.HK) is 236.10, compared to its 5-year average forward P/E of 165.24. For a more detailed relative valuation and DCF analysis to assess 's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
165.24
Current PE
236.10
Overvalued PE
547.37
Undervalued PE
-216.88

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
31.24
Current EV/EBITDA
132.60
Overvalued EV/EBITDA
237.40
Undervalued EV/EBITDA
-174.92

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
18.28
Current PS
21.50
Overvalued PS
32.71
Undervalued PS
3.84

Financials

AI Analysis
Annual
Quarterly

Whales Holding 09926

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is (09926) stock price today?

The current price of 09926 is 106.5 USD — it has increased 4.41

What is (09926)'s business?

What is the price predicton of 09926 Stock?

Wall Street analysts forecast 09926 stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for 09926 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is (09926)'s revenue for the last quarter?

revenue for the last quarter amounts to NaN USD, decreased

What is (09926)'s earnings per share (EPS) for the last quarter?

. EPS for the last quarter amounts to USD, decreased

How many employees does (09926). have?

(09926) has 0 emplpoyees as of March 06 2026.

What is (09926) market cap?

Today 09926 has the market capitalization of 0.00 USD.